Terms: = Kidney tumors AND ACSL3, PRO2194, 2181, ENSG00000123983, O95573, FACL3, ACS3
4 results:
1. Prognostic Role of Long-Chain Acyl-Coenzyme A Synthetase Family Genes in Patients with Clear Cell Renal Cell Carcinoma: A Comprehensive Bioinformatics Analysis Confirmed with External Validation Cohorts.
Temiz MZ; Colakerol A; Sonmez SZ; Gokce A; Canitez IO; Ozsoy S; Kandirali E; Semercioz A; Muslumanoglu AY
Clin Genitourin Cancer; 2023 Feb; 21(1):91-104. PubMed ID: 36529627
[TBL] [Abstract] [Full Text] [Related]
2. Screening of Differentially Expressed Iron Death-Related Genes and the Construction of Prognosis Model in Patients with Renal Clear Cell Carcinoma.
Wu D; Xu Z; Shi Z; Li P; Lv H; Huang J; Fu D
Comput Math Methods Med; 2022; 2022():4456987. PubMed ID: 36081434
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Tannir NM; Agarwal N; Porta C; Lawrence NJ; Motzer R; McGregor B; Lee RJ; Jain RK; Davis N; Appleman LJ; Goodman O; Stadler WM; Gandhi S; Geynisman DM; Iacovelli R; Mellado B; Sepúlveda Sánchez JM; Figlin R; Powles T; Akella L; Orford K; Escudier B
JAMA Oncol; 2022 Oct; 8(10):1411-1418. PubMed ID: 36048457
[TBL] [Abstract] [Full Text] [Related]
4. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
[TBL] [Abstract] [Full Text] [Related]
